Europe Genetic Testing Market Size (2024 - 2029)

The Europe Genetic Testing Market is projected to experience significant growth over the forecast period, driven by an increasing emphasis on early disease detection, the demand for personalized medicine, and the expanding application of genetic testing in oncology. The market's expansion is further supported by product launches, collaborations, and agreements within the genetic testing sector. Despite the positive momentum, challenges such as the high cost of genetic tests and the social and ethical implications associated with them may impede market growth.

Market Size of Europe Genetic Testing Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Europe Genetic Testing Market Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
Market Size (2024) USD 6.17 Billion
Market Size (2029) USD 10.19 Billion
CAGR (2024 - 2029) 10.55 %
Market Concentration Low

Major Players

Europe Genetic Testing Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Europe Genetic Testing Market Analysis

The Europe Genetic Testing Market size is estimated at USD 6.17 billion in 2024, and is expected to reach USD 10.19 billion by 2029, growing at a CAGR of 10.55% during the forecast period (2024-2029).

  • COVID-19 had a significant impact on the genetic testing market during the initial phases of the pandemic. Genetic testing helps identify variations that affect the response to COVID-19 and may lead to discovering new therapies that could reduce harm, save lives, and even prevent future outbreaks. In 2021, Genomtec launched the first genetic diagnostic test, SARS-Cov-2 EvaGreen Direct-RT-LAMP CE-IVD Kit, which enables the identification of SARS-CoV-2 infection from the patient's saliva in the European Union. Thus, the demand for genetic testing has experienced suddenly spiked due to the pandemic.
  • However, according to the study published in Prenatal Diagnosis in March 2021, the COVID-19 pandemic may influence pregnant women's decisions about prenatal genetic testing. Patients' access to and use of prenatal genetic tests may be impacted by the pandemic. Hence, such a restraining factor imposed an adverse impact on the market initially, however, in later times the positive developments, such as COVID-19 related product launch, helped the market to gain positive momentum, thereby propelling the market growth.
  • Genetic testing has been growing at an unprecedented rate, a large panel of tests is now available to screen a number of genetic diseases. Treatment is available for several rare genetic diseases and the procedure is gaining importance in scenarios, such as carrier testing, newborn screening, predictive and pre-symptomatic testing, etc. The major factors driving the growth of the European genetic testing market include increasing emphasis on early disease detection and prevention, increasing demand for personalized medicine, and increasing application of genetic testing in oncology, among others. For instance, in February 2022, the European Commission publicized four new European Union Cancer Plan activities to help Member States address inequalities, improve Human papillomavirus infection screening and vaccination, and support cancer survivors. This is anticipated to increase the diagnosis and genetic testing of cancer in the European nations for the early detection of cancers, thereby expected to drive the growth of this market.
  • Furthermore, product launches, collaborations, and agreements relating to the genetic testing field are anticipated to boost market growth in Europe over the forecast period. For instance, in February 2022, Microbiome DX company Genetic Analysis AS and Institut für Medizinische Diagnostik, a part of the Medicover Group, launched the GA-map Dysbiosis Test in Germany. IMD was likely to activate its new Microbiome laboratory in February 2022 and add standardized microbiota testing to its existing test portfolio of products. This new Microbiota test offering is anticipated to be marketed to customers in Germany and Europe. Furthermore, in October 2021, Blueprint Genetics and BioMarin collaborated to launch a sponsored testing program for individuals with skeletal dysplasia in Europe. Hence, such collaborations and product launches are anticipated to boost the genetic testing market in Europe over the forecast period.
  • Therefore, due to the increasing focus on early disease detection and prevention, increasing demand for personalized medicine, and increasing application of genetic testing in oncology, the genetic testing market in Europe is anticipated to witness growth over the forecast period. However, the high cost of genetic tests and social and ethical implications associated with genetic testing are the factors, that are expected to hinder the market growth.

Europe Genetic Testing Industry Segmentation

As per the scope of this report, genetic testing is a test performed to identify the presence of a particular gene/s with a particular sequence of the genome. The gene/s can be identified either directly through sequencing or indirectly through various methods.

The European Genetic Testing market is segmented by type (carrier testing, diagnostic testing, newborn screening, predictive and presymptomatic testing, prenatal testing, other types), by disease (Alzheimer's disease, cancer, cystic fibrosis, sickle cell anemia, Duchenne muscular dystrophy, thalassemia, Huntington's disease, other diseases), by technology (cytogenetic testing, biochemical testing, and molecular testing), and geography (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe).

The report offers the value (in USD million) for the above segments.

By Type
Carrier Testing
Diagnostic Testing
Newborn Screening
Predictive and Presymptomatic Testing
Prenatal Testing
Other Types
By Disease
Alzheimer's Disease
Cancer
Cystic Fibrosis
Sickle Cell Anemia
Duchenne Muscular Dystrophy
Thalassemia
Huntington's Disease
Other Diseases
By Technology
Cytogenetic Testing
Biochemical Testing
Molecular Testing
Geography
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region Or Segment?
Customize Now

Europe Genetic Testing Market Size Summary

The European genetic testing market is poised for significant growth, driven by an increasing emphasis on early disease detection, personalized medicine, and the expanding application of genetic testing in oncology. The market has experienced a surge in demand, particularly due to the COVID-19 pandemic, which highlighted the importance of genetic testing in understanding and combating the virus. The introduction of innovative products, such as the SARS-CoV-2 EvaGreen Direct-RT-LAMP CE-IVD Kit, underscored the role of genetic testing in public health. Despite initial challenges posed by the pandemic, such as reduced access to prenatal genetic testing, the market has rebounded, supported by new product launches and collaborations. These developments are expected to propel the market forward, with diagnostic testing emerging as a key segment due to the rising incidence of chronic diseases and cancer in Europe.

The United Kingdom is expected to be a significant contributor to the market's growth, driven by initiatives focused on early disease detection and the benefits of genetic testing in identifying rare diseases. The presence of major market players and favorable regulatory conditions further bolster the market's expansion in this region. The launch of new genetic tests and collaborations aimed at enhancing product availability are anticipated to support market growth. However, challenges such as the high cost of genetic tests and ethical considerations may hinder progress. Overall, the European genetic testing market is characterized by moderate competition, with technological advancements and product innovations playing a crucial role in shaping its trajectory.

Explore More

Europe Genetic Testing Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Emphasis on Early Disease Detection and Prevention

      2. 1.2.2 Increasing Demand for Personalized Medicine

      3. 1.2.3 Increasing Application of Genetic Testing in Oncology

    3. 1.3 Market Restraints

      1. 1.3.1 High Costs of Genetic Testing

      2. 1.3.2 Social and Ethical Implications of Genetic Testing

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Type

      1. 2.1.1 Carrier Testing

      2. 2.1.2 Diagnostic Testing

      3. 2.1.3 Newborn Screening

      4. 2.1.4 Predictive and Presymptomatic Testing

      5. 2.1.5 Prenatal Testing

      6. 2.1.6 Other Types

    2. 2.2 By Disease

      1. 2.2.1 Alzheimer's Disease

      2. 2.2.2 Cancer

      3. 2.2.3 Cystic Fibrosis

      4. 2.2.4 Sickle Cell Anemia

      5. 2.2.5 Duchenne Muscular Dystrophy

      6. 2.2.6 Thalassemia

      7. 2.2.7 Huntington's Disease

      8. 2.2.8 Other Diseases

    3. 2.3 By Technology

      1. 2.3.1 Cytogenetic Testing

      2. 2.3.2 Biochemical Testing

      3. 2.3.3 Molecular Testing

    4. 2.4 Geography

      1. 2.4.1 Germany

      2. 2.4.2 United Kingdom

      3. 2.4.3 France

      4. 2.4.4 Italy

      5. 2.4.5 Spain

      6. 2.4.6 Rest of Europe

Europe Genetic Testing Market Size FAQs

The Europe Genetic Testing Market size is expected to reach USD 6.17 billion in 2024 and grow at a CAGR of 10.55% to reach USD 10.19 billion by 2029.

In 2024, the Europe Genetic Testing Market size is expected to reach USD 6.17 billion.

Europe Genetic Testing Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)